about
Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages.Targeting HLA class I expression to increase tumor immunogenicity.Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.Prediction of promiscuous peptides that bind HLA class I molecules.
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
T-cell-directed cancer vaccines: the melanoma model.
@ast
T-cell-directed cancer vaccines: the melanoma model.
@en
T-cell-directed cancer vaccines: the melanoma model.
@nl
type
label
T-cell-directed cancer vaccines: the melanoma model.
@ast
T-cell-directed cancer vaccines: the melanoma model.
@en
T-cell-directed cancer vaccines: the melanoma model.
@nl
prefLabel
T-cell-directed cancer vaccines: the melanoma model.
@ast
T-cell-directed cancer vaccines: the melanoma model.
@en
T-cell-directed cancer vaccines: the melanoma model.
@nl
P2093
P2860
P356
P1476
T-cell-directed cancer vaccines: the melanoma model.
@en
P2093
P2860
P304
P356
10.1517/14712598.1.2.277
P407
P577
2001-03-01T00:00:00Z